Overview
- 19 inspections across 19 sites are on record.
- 7 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2022-07-19.
At a glance
Inspections
19
Sites
19
Observations
7
Career since
Aug 2020
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| John P. Nardandrea, M.D. | 19 Jul 2022 | Human Drugs | |
| Matthew W. Doty, M.D. | 1 Jul 2022 | Human Drugs | |
| John K Earl, M.D. | 27 May 2022 | Biologics | |
| Lucas R. Wiegand M.D. | 18 Apr 2022 | Human Drugs | |
| David A. Reichstein, MD | 18 Mar 2022 | Human Drugs |
Sites inspected
John P. Nardandrea, M.D.Ocala, United States1 insp.
Matthew W. Doty, M.D.Miami, United States1 insp.
John K Earl, M.D.Hickory, United States1 insp.
Lucas R. Wiegand M.D.Tampa, United States1 insp.
David A. Reichstein, MDNashville, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Full investigator report
Get the verbatim findings behind Latrice G Jones' 7 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site